Sumo Joe, I think the great opportunity for MDI/MVP is the Continuous Flow Technology. There is a huge demand for drugs and by all accounts MVP has the technology to cost effectively increase drug production. These drugs have been mentioned in a recent article as drugs that hospitals are running out of:fentanyl, versed, propofol, and neuromuscular blockades. I wonder if CF technology can produce these drugs? I think MVP said they have a list of 100 target drugs for CF production and they have already done a trial production run of Lidocaine which has met quality standards. There is no requirement for medical trials, just produce the drugs to prescribed standards and fulfil demand. License the technology out, or build production capacity from scratch?
MVP Price at posting:
$7.85 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)